Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9583.026 | 0.9766 | 0.9632 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9583.026 | 0.9992 | 0.9988 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9583.026 | 0.9844 | 0.9754 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9583.026 | 0.9784 | 0.9659 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9583.026 | 0.9589 | 0.9352 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9583.026 | 0.9952 | 0.9924 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9583.026 | 1.0372 | 1.0582 | 1.2731 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9583.026 | 0.9978 | 0.9966 | 1.2731 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7876.042 | 1.0208 | 1.0379 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7876.042 | 1.0627 | 1.1141 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7876.042 | 1.0218 | 1.0397 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7876.042 | 1.0658 | 1.1198 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7876.042 | 1.0437 | 1.0797 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7876.042 | 1.0437 | 1.0797 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7876.042 | 1.0373 | 1.0679 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7876.042 | 0.9551 | 0.9178 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7876.042 | 0.9718 | 0.9484 | 1.0958 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7877.042 | 0.9787 | 0.8779 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7877.042 | 0.9964 | 0.9791 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7877.042 | 0.9839 | 0.9072 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7877.042 | 1.0279 | 1.1678 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7877.042 | 1.0074 | 1.0438 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7877.042 | 0.9904 | 0.9440 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7877.042 | 1.0309 | 1.1866 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7877.042 | 0.9845 | 0.9103 | 0.3414 |